$SONO breakdown 📊
✅ Q4 beat: adj EPS $0.04 (a profit), revenue $344M +20% YoY
✅ $150M buyback, ~7% of the company
✅ Broke out of a 6-month $13-$18.40 box
⚠️ Now testing ~$20, the ceiling from 2024 & 2025
Close over $20 on volume = room to run. NFA
44
$VFF in at $2.93 📈
Q3 beat: EPS $0.08 vs $0.05, sales $66.9M vs $64.4M. Profitable, no offering. Spiked to $3.14, flushed to $2.76, bought back on ~7x volume. 30-min KST back over zero.
Needs $3.02, then $3.19. Support $2.80, then $2.67.
#VFF #cannabis #smallcaps #earnings
1
176
$III in at $6.20 📈
Q3 earnings: AI revenue topped $30M for the first time. Flushed to $5.42 at the open, then fully bought back. 30-min KST crossed back above zero on ~3x volume.
Watching $6.30 breakout. Support $6.00.
#III #smallcaps #stocks #daytrading #earnings
80
$ATWT still one of the cleaner OTC setups I’m watching. Park-Aid closed, new CEO in place, share count held steady in Q1, and chart looks interesting if .0027 support holds. Needs follow-through above .0034. NFA
1
4
323
Quick $LBRG read: tight float, AI/manufacturing story, and KST curling after a long base. Still high-risk OTC with preferred structure + restructuring history. Watching .0058-.0062 and .007+ for confirmation. NFA
162
Think of it like pizza. We had a small pizza, and now we're cutting it into more slices ($BLEG dilution). But those new slices are how we bought a much, much bigger pizza with better toppings! Your smaller piece is now part of a giant, amazing pizza. 🍕🙂
1
1
112
Imagine $BLEG was a messy toy box. Now, a new grown up came with a special LEGO set! We gave away some toy coupons to get it, but this LEGO set can build a whole city! Don't listen to the kids who are still playing with the old, broken toys. 🚀
The dilution authorized billions of shares to acquire a company with a patented device & a team projecting $40M in revenue At a P/S of just 1 that's a $40M market cap. Comparing that value to a $0002 price is missing the point. Dilution is the cost of a transformative deal $BLEG
The intrinsic value of $BLEG post-merger hinges on commercializing its patented intranasal drug delivery. If the $40M revenue target is met, a 2x P/S multiple (still modest for biotech) could elevate market cap to $80M, translating to a share price of ~$0.042.
2
1
214
A successful $BLEG merger, achieving its projected $40M first-year revenue, could fundamentally re-rate its valuation. At a conservative 1x Price-to-Sales multiple, this implies a $40M market cap, driving shares to ~$0.021 from current ~$0.0008(based on ~1.9B implied shares).
1
114
The core technology acquired by $BLEG demonstrates superior absorption kinetics: 7x higher absorption in 4 mins & 4x higher in 10 mins vs. solution-based drugs in clinical studies. This PBI platform is a key differentiator. #Biopharma #Intranasal #DrugDevelopment
103
$BLEG's merger targets the burgeoning Naloxone market, valued at $1.07B in 2023 and projected to reach $2.48B by 2032. Their patented all-in-one intranasal device aims for cost reduction & enhanced precision. #Naloxone #DrugDelivery #OpioidCrisis
73
The addiction therapeutics market, targeted by $BLEG's merger, is projected to grow from $9B in 2023 to $16.7B by 2033, demonstrating a 6.6% CAGR. This significant market expansion underpins the combined entity's growth strategy. #Healthcare #MarketAnalysis #CAGR
62













